Insulet to Present at Upcoming Investor Conferences

Rhea-AI Summary

Insulet Corporation (NASDAQ: PODD), a leader in tubeless insulin pump technology, has announced participation in four key investor conferences. Scheduled presentations include the Canaccord Genuity Growth Conference on August 10, Wells Fargo Healthcare Conference on September 9, Morgan Stanley Healthcare Conference on September 13, and Baird Global Healthcare Conference on September 14, 2022. Audio webcasts will be made available for live and replay access on Insulet's investor relations website.

Insulet is known for its Omnipod product platform, which offers innovative insulin delivery solutions.

ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod^® brand of products, today announced that management will present at four upcoming investor conferences (all Eastern Time):

• The Canaccord Genuity 42^nd Annual Growth Conference on Wednesday, August 10, 2022, at 4:30 p.m.
• The 2022 Wells Fargo Healthcare conference on Friday, September 9, 2022, at 8:00 a.m.
• The Morgan Stanley 20^th Annual Global Healthcare Conference on Tuesday, September 13, 2022, at 3:30 p.m.
• The Baird 2022 Global Healthcare Conference on Wednesday, September 14, 2022, at 12:15 p.m.

To listen to the live audio webcasts of the presentations, please visit investors.insulet.com/events. Replays of the webcasts will also be available following the events.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s latest innovation, the Omnipod^® 5 Automated Insulin Delivery System, is a tubeless automated insulin delivery system, integrated with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and is fully controlled by a compatible personal smartphone. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit: insulet.com and omnipod.com.

©2022 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220805005006/en/

Investor Relations:

Deborah R. Gordon

Vice President, Investor Relations

(978) 600-7717

dgordon@insulet.com

Merrill Robichaud

Investor Relations Coordinator

(978) 932-0444

mrobichaud@insulet.com

Media:

Angela Geryak Wiczek

Senior Director, Corporate Communications

(978) 932-0611

awiczek@insulet.com

Source: Insulet Corporation

FAQ

What investor conferences will Insulet Corporation (PODD) attend in 2022?

Insulet Corporation (PODD) will attend the Canaccord Genuity Growth Conference on August 10, Wells Fargo Healthcare Conference on September 9, Morgan Stanley Healthcare Conference on September 13, and Baird Global Healthcare Conference on September 14.

Where can I listen to the live presentations from Insulet Corporation's investor conferences?

You can listen to the live audio webcasts of Insulet Corporation's presentations on their investor relations website.

What is the focus of Insulet Corporation's Omnipod product platform?

The Omnipod product platform focuses on providing innovative and convenient tubeless insulin delivery solutions for people with diabetes.

When will Insulet Corporation present at the Wells Fargo Healthcare Conference?

Insulet Corporation will present at the Wells Fargo Healthcare Conference on September 9, 2022, at 8:00 a.m. Eastern Time.

What type of technology does Insulet Corporation specialize in?

Insulet Corporation specializes in tubeless insulin pump technology, significantly simplifying insulin delivery for diabetes management.